PolTREG and U.S. Subsidiary Immuthera Secure Positive FDA Opinion, Paving the Way for a Registrational Pre-Symptomatic Type 1 Diabetes Trial FDA agreed that PolTREG’s clinical data in Stage 3 Type 1 Diabetes (T1D) appears sufficient to support the Prospect …